[Federal Register Volume 75, Number 56 (Wednesday, March 24, 2010)]
[Notices]
[Page 14190]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-6415]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on December 4, 2009, Sigma
Aldrich Research Biochemicals, Inc., 1-3 Strathmore Road, Natick,
Massachusetts 01760-2447, made application by renewal to the Drug
Enforcement Administration (DEA) as a bulk manufacturer of the basic
classes of controlled substances in schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cathinone (1235)........................... I
Methcathinone (1237)....................... I
Aminorex (1585)............................ I
Alpha-ethyltryptamine (7249)............... I
Lysergic acid diethylamide (7315).......... I
Tetrahydrocannabinols (7370)............... I
------------------------------------------------------------------------
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
4-Bromo-2,5-dimethoxyamphetamine (7391).... I
4-Bromo-2,5-dimethoxyphenethylamine (7392). I
2,5-Dimethoxyamphetamine (7396)............ I
3,4-Methylenedioxyamphetamine (7400)....... I
N-Hydroxy-3,4-methylenedioxyamphetamine I
(7402).
3,4-Methylenedioxy-N-ethylamphetamine I
(7404).
3,4-Methylenedioxymethamphetamine (MDMA) I
(7405).
Psilocybin (7437).......................... I
5-Methoxy-N,N-diisopropyltryptamine (7439). I
1-[1-(2-Thienyl)cyclohexyl]piperidine (TCP) I
(7470).
N-Benzylpiperazine (BZP) (7493)............ I
Heroin (9200).............................. I
Normorphine (9313)......................... I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Nabilone (7379)............................ II
1-Phenylcyclohexylamine (7460)............. II
Phencyclidine (7471)....................... II
Cocaine (9041.............................. II
Codeine (9050)............................. II
Diprenorphine (9058)....................... II
Ecgonine (9180)............................ II
------------------------------------------------------------------------
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Levomethorphan (9210)...................... II
Levorphanol (9220)......................... II
Meperidine (9230).......................... II
Metazocine (9240).......................... II
Methadone (9250)........................... II
Morphine (9300)............................
II Thebaine (9333)......................... II
Levo-alphacetylmethadol (9648)............. II
Remifentanil (9739)........................ II
Carfentanil (9743)......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture reference standards.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such a substance, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, VA 22152; and must be filed no later
than May 24, 2010.
Dated: March 16, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2010-6415 Filed 3-23-10; 8:45 am]
BILLING CODE 4410-09-P